PART I FINANCIAL INFORMATION [Condensed Consolidated Financial Statements (Unaudited)](index=3&type=section&id=Item%201.%20Condensed%20Consolidated%20Financial%20Statements%20(Unaudited)) This section presents the unaudited condensed consolidated financial statements for the three and six months ended June 30, 2021, detailing financial position, operations, and cash flows, with a net loss of $156.8 million and sufficient liquidity for the next twelve months Condensed Consolidated Balance Sheet Highlights (in thousands) | Account | June 30, 2021 | December 31, 2020 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $82,763 | $67,329 | | Short-term investments | $573,605 | $562,108 | | Total Current Assets | $666,640 | $636,100 | | Total Assets | $852,790 | $768,458 | | **Liabilities & Equity** | | | | Total Current Liabilities | $60,534 | $54,871 | | Total Liabilities | $108,377 | $111,960 | | Total Stockholders' Equity | $744,413 | $656,498 | Condensed Consolidated Statements of Operations (in thousands, except per share data) | Metric | Three Months Ended June 30, 2021 | Three Months Ended June 30, 2020 | Six Months Ended June 30, 2021 | Six Months Ended June 30, 2020 | | :--- | :--- | :--- | :--- | :--- | | Research and development expenses | $62,119 | $49,274 | $118,068 | $106,226 | | General and administrative expenses | $19,307 | $14,353 | $38,928 | $28,211 | | Loss from operations | $(81,426) | $(63,627) | $(156,996) | $(134,437) | | Net Loss | $(81,351) | $(63,018) | $(156,800) | $(132,613) | | Net Loss Per Share, Basic and Diluted | $(0.53) | $(0.47) | $(1.04) | $(1.02) | Condensed Consolidated Statements of Cash Flows (in thousands) | Cash Flow Activity | Six Months Ended June 30, 2021 | Six Months Ended June 30, 2020 | | :--- | :--- | :--- | | Net cash used in operating activities | $(116,399) | $(101,927) | | Net cash used by investing activities | $(81,954) | $(323,651) | | Net cash provided by financing activities | $214,346 | $572,298 | - The company is a clinical-stage biopharmaceutical firm focused on developing and commercializing **TIL cell therapies** for cancer, with **lifileucel** as its lead product candidate for metastatic melanoma and cervical cancer, utilizing a proprietary **Gen 2 manufacturing process**[25](index=25&type=chunk) - As of June 30, 2021, the company held **$708.7 million** in cash, cash equivalents, and investments, which management deems sufficient to fund operations for at least the **next twelve months**, despite a **net loss of $156.8 million** for the first half of 2021 and no commercial revenue[27](index=27&type=chunk)[28](index=28&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=35&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses the company's clinical-stage operations, focusing on TIL therapies, with a BLA for lifileucel in melanoma now expected in H1 2022, alongside increased operating expenses and a strong liquidity position [Overview](index=35&type=section&id=Overview) This overview details the company's focus on TIL cell therapies, particularly lifileucel, with a BLA submission for metastatic melanoma now anticipated in H1 2022 pending FDA feedback, alongside progress in other pivotal and combination trials - The **BLA submission for lifileucel in metastatic melanoma** is now anticipated in **H1 2022**, pending resolution of FDA feedback on potency assays[156](index=156&type=chunk) - Lifileucel demonstrated a **36% objective response rate (ORR)** in the C-144-01 trial for metastatic melanoma (Cohort 2), with median duration of response (DOR) not yet reached after **33.1 months** of median follow-up[154](index=154&type=chunk) - In the C-145-04 trial for metastatic cervical cancer, lifileucel achieved a **44% ORR** in 27 patients, with median DOR not yet reached[157](index=157&type=chunk) - Combination therapy of lifileucel with pembrolizumab showed an **86% ORR** in melanoma (IOV-COM-202 Cohort 1A) and a **44% ORR** in HNSCC (Cohort 2A), while LN-145 monotherapy in NSCLC (Cohort 3B) achieved a **21.4% ORR**[162](index=162&type=chunk)[163](index=163&type=chunk)[164](index=164&type=chunk) [Results of Operations](index=41&type=section&id=Results%20of%20Operations) For the six months ended June 30, 2021, R&D expenses increased by 11% to $118.1 million, and G&A expenses increased by 38% to $38.9 million, leading to an 18% rise in net loss to $156.8 million Change in Research and Development Expenses (in thousands) | Period | 2021 | 2020 | Change ($) | Change (%) | | :--- | :--- | :--- | :--- | :--- | | **Three Months Ended June 30** | $62,119 | $49,274 | $12,845 | 26% | | **Six Months Ended June 30** | $118,068 | $106,226 | $11,842 | 11% | - The **11% increase in H1 2021 R&D expense** was primarily due to a **$14.0 million increase in payroll**, an **$8.0 million increase in stock-based compensation**, and a **$4.0 million increase in commercial manufacturing facility activities**, partially offset by a **$10.0 million license cost** recognized in 2020[179](index=179&type=chunk) Change in General and Administrative Expenses (in thousands) | Period | 2021 | 2020 | Change ($) | Change (%) | | :--- | :--- | :--- | :--- | :--- | | **Three Months Ended June 30** | $19,307 | $14,353 | $4,954 | 35% | | **Six Months Ended June 30** | $38,928 | $28,211 | $10,717 | 38% | - The **38% increase in H1 2021 G&A expense** was mainly due to a **$4.7 million increase in payroll**, a **$3.4 million increase in stock-based compensation**, and a **$2.3 million increase in intellectual property, insurance, and license fees**[181](index=181&type=chunk) [Liquidity and Capital Resources](index=43&type=section&id=Liquidity%20and%20Capital%20Resources) The company has historically funded operations through equity offerings, holding $82.8 million in cash and $619.9 million in investments as of June 30, 2021, with management believing existing capital is sufficient for at least the next 12 months - As of June 30, 2021, the company had **$82.8 million in cash and cash equivalents**, **$619.9 million in investments**, and **$744.4 million in stockholders' equity**[193](index=193&type=chunk) - In the first six months of 2021, the company received net proceeds of approximately **$203.2 million** from its "at the market" offering program by selling **6,474,099 shares**[191](index=191&type=chunk) - Management believes that available funds are sufficient to fund anticipated operating expenses and capital expenditures for at least **12 months** from the filing date of this report[194](index=194&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=46&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company's market risk exposure is primarily limited to interest income sensitivity from its portfolio of cash and short-term debt securities, with a hypothetical 1% interest rate change impacting fair value by approximately $2.7 million - The company's primary market risk is **interest rate sensitivity** on its investment portfolio, which consists mainly of short-term U.S. government debt securities[206](index=206&type=chunk) - A **1% change in interest rates** as of June 30, 2021, would cause the fair value of the investment portfolio to change by approximately **$2.7 million**[206](index=206&type=chunk) [Controls and Procedures](index=46&type=section&id=Item%204.%20Controls%20and%20Procedures) Based on management's evaluation, the company's disclosure controls and procedures were effective as of June 30, 2021, with no material changes to internal control over financial reporting during the quarter - Management, including the CEO and CFO, concluded that **disclosure controls and procedures were effective** as of the end of the quarter[207](index=207&type=chunk) - No changes in internal control over financial reporting occurred during the quarter ended June 30, 2021, that materially affected, or are reasonably likely to materially affect, internal controls[208](index=208&type=chunk) PART II OTHER INFORMATION [Legal Proceedings](index=46&type=section&id=Item%201.%20Legal%20Proceedings) This section incorporates by reference the legal proceedings detailed in Note 9 of the financial statements, including a stockholder derivative complaint and two ongoing lawsuits initiated by Solomon Capital, LLC, which the company intends to vigorously defend - The company is facing a **stockholder derivative complaint** filed in December 2020, alleging breach of fiduciary duty related to excessive compensation for certain non-executive directors[115](index=115&type=chunk) - Two lawsuits are ongoing with **Solomon Capital, LLC**, concerning alleged agreements from 2012 for financing services and equity claims, which the company is defending against and has asserted counterclaims[116](index=116&type=chunk)[118](index=118&type=chunk)[119](index=119&type=chunk) [Risk Factors](index=46&type=section&id=Item%201A.%20Risk%20Factors) This section details significant risks, including substantial dependence on product candidate success, potential delays in clinical trials and regulatory approval due to FDA feedback on potency assays, complexities in manufacturing cell-based therapies, intense competition, and challenges in market acceptance and reimbursement - The company is substantially dependent on the success of its product candidates, which may never receive regulatory approval or be successfully commercialized[220](index=220&type=chunk) - The **BLA submission for lifileucel has been delayed to H1 2022** due to the need to resolve FDA feedback on potency assays, highlighting regulatory risk and uncertainty[268](index=268&type=chunk)[374](index=374&type=chunk) - Manufacturing of cell-based therapies is complex and susceptible to product loss, contamination, and scalability issues, with the company relying on third-party CMOs and building its own facility, both carrying significant risks[263](index=263&type=chunk)[264](index=264&type=chunk)[269](index=269&type=chunk) - The business could be adversely affected by health epidemics like the **COVID-19 pandemic**, which could disrupt clinical trials, supply chains, and commercial launch preparations[352](index=352&type=chunk)[356](index=356&type=chunk) - The company faces intense competition from other biotechnology companies with greater resources, and its novel therapies may struggle to gain market acceptance and adequate reimbursement coverage[307](index=307&type=chunk)[317](index=317&type=chunk) [Unregistered Sales of Securities and Use of Proceeds](index=116&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Securities%20and%20Use%20of%20Proceeds) The company reported no unregistered sales of securities or use of proceeds for the period - Nothing to report for this item[450](index=450&type=chunk) [Defaults Upon Senior Securities](index=116&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) The company reported no defaults upon senior securities for the period - Nothing to report for this item[451](index=451&type=chunk) [Mine Safety Disclosure](index=118&type=section&id=Item%204.%20Mine%20Safety%20Disclosure) The company reported no mine safety disclosures for the period - Nothing to report for this item[452](index=452&type=chunk) [Other Information](index=118&type=section&id=Item%205.%20Other%20Information) The company reported no other information for the period - Nothing to report for this item[453](index=453&type=chunk) [Exhibits](index=119&type=section&id=Item%206.%20Exhibits) This section lists the exhibits filed with the quarterly report, including the Amended and Restated Patent License Agreement with the National Institutes of Health, forms of equity award agreements under the 2018 Equity Incentive Plan, and certifications by the Chief Executive Officer and Chief Financial Officer - Key exhibits filed include an **Amended and Restated Patent License Agreement with the NIH** and forms for stock unit and stock option agreements related to June 2021 retention equity awards[456](index=456&type=chunk) Signatures [Signatures](index=120&type=section&id=Signatures) The report was duly signed and authorized on August 5, 2021, by Frederick G. Vogt, Ph.D., Esq., as Interim Chief Executive Officer and President, and Jean-Marc Bellemin, as Chief Financial Officer and Treasurer - The report was signed on **August 5, 2021**, by **Frederick G. Vogt, Ph.D., Esq.** (Interim CEO) and **Jean-Marc Bellemin** (CFO)[461](index=461&type=chunk)

ASCO Update Call June 6, 2021 © 2021, Iovance Biotherapeutics, Inc 1 | --- | --- | |---------------------------------------------------------------------------------------------------------------------------|-------------------------| | Agenda | | | | | | • Corporate Update : Fred Vogt, incoming Interim CEO and President • ASCO Updates for Lifileucel in Advanced Melanoma | : Omid Hamid, MD, Chief | | of Research/Immuno-Oncology, The Angeles Clinic & Research Institute | | | • Financial Summary : Jean-Marc B ...

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q1 2021 Earnings Conference Call May 6, 2021 4:30 PM ET Company Participants Maria Fardis - Chief Executive Officer & President Friedrich Finckenstein - Chief Medical Officer Jean Marc Bellemin - Chief Financial Officer Sara Pellegrino - Vice President, Investor and Public Relations Jim Ziegler - Senior Vice President, Commercial Conference Call Participants Michael Yee - Jefferies LLC Peter Lawson - Barclays Bank Mark Breidenbach - Oppenheimer Boris Peaker - Cowe ...

[PART I FINANCIAL INFORMATION](index=4&type=section&id=PART%20I%20FINANCIAL%20INFORMATION) [Item 1. Condensed Consolidated Financial Statements (Unaudited)](index=4&type=section&id=Item%201.%20Condensed%20Consolidated%20Financial%20Statements%20(Unaudited)) This section provides the unaudited condensed consolidated financial statements for Iovance Biotherapeutics, Inc., detailing its financial position and performance - The company is a clinical-stage biopharmaceutical company focused on developing and commercializing cell therapies, specifically Tumor Infiltrating Lymphocyte (TIL) therapy, with lead candidates lifileucel for metastatic melanoma and cervical cancer[25](index=25&type=chunk) - The company has not generated any revenue and incurred a net loss of **$75.4 million** for the three months ended March 31, 2021, though management believes existing capital is sufficient for the next twelve months[27](index=27&type=chunk)[28](index=28&type=chunk) [Condensed Consolidated Balance Sheets](index=4&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) The balance sheet shows total assets decreased slightly to **$750.6 million** as of March 31, 2021, primarily due to reduced short-term investments Condensed Consolidated Balance Sheet Highlights (in thousands) | Account | March 31, 2021 | December 31, 2020 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $131,954 | $67,329 | | Short-term investments | $461,976 | $562,108 | | Total Current Assets | $605,218 | $636,100 | | Total Assets | $750,573 | $768,458 | | **Liabilities & Equity** | | | | Total Current Liabilities | $55,059 | $54,871 | | Total Liabilities | $103,142 | $111,960 | | Total Stockholders' Equity | $647,431 | $656,498 | [Condensed Consolidated Statements of Operations](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) The company reported a net loss of **$75.4 million** for Q1 2021, an increase from the prior year, primarily due to higher general and administrative expenses Statement of Operations Summary (in thousands, except per share data) | Item | Three Months Ended March 31, 2021 | Three Months Ended March 31, 2020 | | :--- | :--- | :--- | | Research and development expenses | $55,949 | $56,952 | | General and administrative expenses | $19,621 | $13,858 | | Total costs and expenses | $75,570 | $70,810 | | Loss from operations | ($75,570) | ($70,810) | | Net Loss | ($75,449) | ($69,595) | | Net Loss Per Share, Basic and Diluted | ($0.51) | ($0.55) | [Condensed Consolidated Statements of Cash Flows](index=8&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Net cash used in operating activities was **$62.4 million** in Q1 2021, offset by cash from investing and financing, leading to a **$65.2 million** net increase in cash Cash Flow Summary (in thousands) | Activity | Three Months Ended March 31, 2021 | Three Months Ended March 31, 2020 | | :--- | :--- | :--- | | Net cash used in operating activities | ($62,391) | ($65,292) | | Net cash provided by investing activities | $77,211 | $100,105 | | Net cash provided by financing activities | $50,364 | $3,833 | | **Net increase in cash, cash equivalents, and restricted cash** | **$65,184** | **$38,646** | [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=48&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses financial condition and operational results, highlighting clinical program progress, expense changes, and liquidity, while noting BLA submission delays and COVID-19 impacts [Overview and Clinical Development](index=48&type=section&id=Overview%20and%20Clinical%20Development) This section provides an overview of the company's TIL cell therapy development, focusing on lifileucel's clinical progress in melanoma and cervical cancer, including BLA submission updates - The Biologics License Application (BLA) for lifileucel in metastatic melanoma was delayed due to FDA feedback on potency assays, with submission now anticipated in **2021**[176](index=176&type=chunk) - In the C-144-01 trial for metastatic melanoma (Cohort 2), lifileucel demonstrated an objective response rate (ORR) of **36%** in 66 patients, with a median duration of response (DOR) not yet reached after **28.1 months** of follow-up[173](index=173&type=chunk) - For metastatic cervical cancer (C-145-04), lifileucel showed an ORR of **44%** in 27 patients and received Breakthrough Therapy Designation, with BLA submission discussions planned for **2021**[177](index=177&type=chunk) [Results of Operations](index=55&type=section&id=Results%20of%20Operations) Q1 2021 results show a **2%** decrease in R&D expenses to **$55.9 million** and a **42%** increase in G&A expenses to **$19.6 million**, leading to an **8%** higher net loss Comparison of Operating Expenses (in thousands) | Expense Category | Q1 2021 | Q1 2020 | Change ($) | Change (%) | | :--- | :--- | :--- | :--- | :--- | | Research and development | $55,949 | $56,952 | ($1,003) | (2)% | | General and administrative | $19,621 | $13,858 | $5,763 | 42% | - The decrease in R&D expense was primarily due to a **$10.0 million** license cost from Novartis recognized in Q1 2020 and a **$5.0 million** decrease in manufacturing costs in Q1 2021[201](index=201&type=chunk) - The increase in G&A expense was mainly driven by a **$2.8 million** increase in payroll and a **$2.6 million** increase in stock-based compensation[202](index=202&type=chunk) [Liquidity and Capital Resources](index=57&type=section&id=Liquidity%20and%20Capital%20Resources) As of March 31, 2021, the company held **$604.2 million** in cash and investments, with management confident in sufficient capital for at least the next 12 months despite expected increased spending - As of March 31, 2021, the company had **$604.2 million** in cash, cash equivalents, and investments[216](index=216&type=chunk)[322](index=322&type=chunk) - In Q1 2021, the company received approximately **$42.9 million** in net proceeds from its 'at the market' (ATM) offering program by selling **1,278,243 shares**[214](index=214&type=chunk)[88](index=88&type=chunk) - Management believes that existing capital is sufficient to fund anticipated operating expenses and capital expenditures for at least **12 months** from the filing date[217](index=217&type=chunk) [Item 3. Quantitative and Qualitative Disclosures About Market Risk](index=60&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company's primary market risk is interest rate sensitivity on its **$472.2 million** investment portfolio, with a **1%** rate change impacting fair value by **$1.9 million** - The company's main market risk is interest income sensitivity from its **$472.2 million** in marketable securities, primarily short-term U.S. government debt[229](index=229&type=chunk) - A hypothetical **1%** change in interest rates would cause the fair value of the investment portfolio to change by approximately **$1.9 million**[229](index=229&type=chunk) [Item 4. Controls and Procedures](index=60&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that disclosure controls and procedures were effective as of March 31, 2021, with no material changes to internal control over financial reporting during the quarter - Management, including the principal executive and financial officers, concluded that disclosure controls and procedures were effective as of the end of the quarter[230](index=230&type=chunk) - No changes in internal control over financial reporting occurred during the quarter that have materially affected, or are reasonably likely to materially affect, these controls[231](index=231&type=chunk) [PART II OTHER INFORMATION](index=61&type=section&id=PART%20II%20OTHER%20INFORMATION) [Item 1. Legal Proceedings](index=61&type=section&id=Item%201.%20Legal%20Proceedings) This section details legal proceedings, including a December 2020 stockholder derivative complaint and ongoing lawsuits with Solomon Capital, LLC, with no other material pending matters - Information on legal proceedings is incorporated by reference from Note 9 to the Condensed Consolidated Financial Statements[232](index=232&type=chunk) - Key legal matters include a derivative lawsuit filed in December 2020 concerning director compensation and lawsuits involving Solomon Capital, LLC[123](index=123&type=chunk)[124](index=124&type=chunk) [Item 1A. Risk Factors](index=61&type=section&id=Item%201A.%20Risk%20Factors) This section outlines key risks, including dependence on product candidate success, clinical trial delays, manufacturing challenges, competition, financing needs, regulatory hurdles, third-party reliance, and health epidemics - The company is substantially dependent on the success of its product candidates and cannot guarantee they will receive regulatory approval or be successfully commercialized[235](index=235&type=chunk)[245](index=245&type=chunk) - The manufacturing of cell-based therapies is complex and subject to difficulties in process development, quality control, and scaling, which could delay or stop the supply of product candidates[235](index=235&type=chunk)[299](index=299&type=chunk) - The company may need additional financing to fund operations and complete development, which may cause dilution to existing stockholders or require relinquishing rights to technologies[235](index=235&type=chunk)[322](index=322&type=chunk) - The business could be adversely affected by health epidemics, including the COVID-19 pandemic, impacting manufacturing, clinical trial sites, and third-party partner operations[239](index=239&type=chunk)[392](index=392&type=chunk) [Item 2. Unregistered Sales of Securities and Use of Proceeds](index=147&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Securities%20and%20Use%20of%20Proceeds) There were no unregistered sales of securities or specific uses of proceeds to report for the period - Nothing to report[505](index=505&type=chunk) [Item 3. Defaults Upon Senior Securities](index=147&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) There were no defaults upon senior securities during the period - Nothing to report[506](index=506&type=chunk) [Item 4. Mine Safety Disclosure](index=147&type=section&id=Item%204.%20Mine%20Safety%20Disclosure) This item is not applicable to the company - Nothing to report[507](index=507&type=chunk) [Item 5. Other Information](index=147&type=section&id=Item%205.%20Other%20Information) There was no other information to report for the period - Nothing to report[508](index=508&type=chunk) [Item 6. Exhibits](index=148&type=section&id=Item%206.%20Exhibits) This section lists exhibits filed with the Form 10-Q, including lease agreements, an executive employment agreement, and required officer certifications - The report includes several exhibits, such as new and amended lease agreements, an executive employment agreement, and required officer certifications[510](index=510&type=chunk) [Signatures](index=149&type=section&id=SIGNATURES) - The report was duly signed and authorized on May 6, 2021, by the Chief Executive Officer, Maria Fardis, and the Chief Financial Officer, Jean-Marc Bellemin[514](index=514&type=chunk)[516](index=516&type=chunk)

| --- | --- | --- | |-------|-------|-------| | | | | | | | | | | | | | --- | --- ...

| --- | --- | --- | |-------|-------|-------| | | | | | | | | | | | | | --- | --- ...

| --- | --- | --- | --- | --- | |---------------------------------------------------------------------------|--------------------------------------|-------|---------------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Tumor Infiltrating Lymphocyte Cell Therapy for Treatment of Solid Tumors | | | February 2021 | | | | © 2021, Iovance Biotherapeutics, Inc | | | 1 | | --- ...

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q4 2020 Earnings Conference Call February 25, 2021 4:30 PM ET Company Participants Maria Fardis - Chief Executive Officer & President Friedrich Finckenstein - Chief Medical Officer Jean Marc Bellemin - Chief Financial Officer Sara Pellegrino - Vice President, Investor and Public Relations Conference Call Participants Mark Breidenbach - Oppenheimer Peter Lawson - Barclays Bank Biren Amin - Jefferies Reni Benjamin - JMP Securities Mara Goldstein - Mizuho Securities ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transaction period from __________ to __________ Commission file number: 001-36860 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Its Charter) Del ...

| --- | --- | --- | --- | --- | |-------------------------------------------------------------------------------------|---------------------------------|-------|---------------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Investigating the Power of Tumor Infiltrating Lymphocytes for Treatment of Cancer | | | November 2020 | | | | © 2020, Iovance Biotherapeutics | | | | ongoing clinical trials and anticipated clinical trials for our current product candidates (including both Company ...